Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epitinib Succinate in Glioblastoma
NCT03231501Phase 1Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epitinib in glioblastoma (GBM), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
epitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03231501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231501.